Detection of recurrent prostate cancer
after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
It was approved by the US Food and Drug Administration on 27 May 2016, and is the first FDA-approved F-18 PET imaging agent indicated for use in patients with suspected recurrent prostate cancer
Locally recurrent prostate cancer
after external beam radiation therapy: diagnostic performance of 1.
73) The increased expression, greater stability, and nuclear localization of AR in recurrent prostate cancers
resistant to androgen deprivation correlated with hypersensitivity to low levels of androgens in these tumors; androgen ablation-resistant prostate cancers required a significantly much lower concentration of dihydrotestosterone than that required by androgen-dependent tumors for stimulation of proliferative activity.
ADT blocks production of androgens--male hormones including testosterone, which fuels tumor growth--and is used primarily in men with advanced or recurrent prostate cancer
Design & Participants: Open-label, single-arm clinical trial of 46 men (ages are not given) with recurrent prostate cancer
with rising prostate-specific antigen (PSA) after surgery or radiotherapy.
The virus was tested in 20 patients who had locally recurrent prostate cancer
following radiotherapy or brachytherapy, said Dr.
Serum prostate-specific antigen (PSA) has been recognized as a sensitive indicator of recurrent prostate cancer
after radical prostatectomy [1-5].
today announced that an interim data analysis showed that its INO-5150 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured in peripheral blood from subjects with biochemically recurrent prostate cancer
Salvage radical prostatectomy offers good long-term oncological outcomes after radiotherapy in patients with biopsy-proven recurrent prostate cancer
No consensus on when and how to detect and cure radio recurrent prostate cancer
exists, but strong evidence indicates that salvage therapies may improve survival rates in patients with prostate cancer.
In a randomized phase III trial comparing thalidomide with placebo in patients with biochemically recurrent prostate cancer
after definitive therapy, thalidomide prolonged progression-free survival, as measured by changes in prostate-specific antigen (PSA) in patients with stage D0 disease, reported Dr.
Now, Life Extension Clinical Research is supporting a clinical trial examining the use of vitamin D in treating slow-growing recurrent prostate cancer
Cryotherapy of the prostate represents a potential treatment for localized recurrent prostate cancer
after radiation therapy, and several studies have reported salvage cryotherapy results with biopsy-proven local failure after external beam radiotherapy.